TY - JOUR T1 - Clinical Trials in Recurrent Ovarian Cancer JF - International Journal of Gynecologic Cancer JO - Int J Gynecol Cancer SP - 771 LP - 775 DO - 10.1097/IGC.0b013e31821bb8aa VL - 21 IS - 4 AU - Michael Friedlander AU - Edward Trimble AU - Anna Tinker AU - David Alberts AU - Elisabeth Avall-Lundqvist AU - Mark Brady AU - Philipp Harter AU - Sandro Pignata AU - Eric Pujade- Lauraine AU - Jalid Sehouli AU - Ignace Vergote AU - Philip Beale AU - Rudd Bekkers AU - Paula Calvert AU - Lawrence Copeland AU - Ros Glasspool AU - Antonio Gonzalez-Martin AU - Dionysis Katsaros AU - Jae Won Kim AU - Brigitte Miller AU - Diane Provencher AU - Lawrence Rubinstein AU - Mostafa Atri AU - Alain Zeimet AU - Monica Bacon AU - Henry Kitchener AU - Gavin C.E. Stuart Y1 - 2011/04/01 UR - http://ijgc.bmj.com/content/21/4/771.abstract N2 - The 4th Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup was held in Vancouver, Canada, in June 2010. Representatives of 23 cooperative research groups studying gynecologic cancers gathered to establish international consensus on issues critical to the conduct of large randomized trials. Group C, 1 of the 3 discussion groups, examined recurrent ovarian cancer, and we report the consensus reached regarding 4 questions. These included the following: (1) What is the role of cytoreductive surgery for recurrent ovarian cancer? (2) How do we define distinct patient populations in need of specific therapeutic approaches? (3) Should end points for trials with recurrent disease vary from those of first-line trials? (4) Is CA-125 progression alone sufficient for entry/eligibility into clinical trials? ER -